SAB Bio signs $36 million minimum-spend manufacturing deal with Emergent for SAB-142
SAB Biotherapeutics entered a Master Manufacturing Services Agreement with Emergent BioSolutions Canada, effective April 28, 2026, under which Emergent will make SAB-142 clinical and commercial supply at its Canadian facility. The agreement sets a minimum aggregate spend of $36 million following any FDA approval of the product, and gives Emergent exclusive manufacturing rights during the term.
Key points
- Agreement effective April 28, 2026, running five years from FDA approval of SAB-142
- Minimum aggregate spend of $36 million following any FDA approval
- Emergent has sole and exclusive right to manufacture the product; batch pricing to be set in a later amendment
- Early termination by Emergent for insolvency, non-payment or material breach triggers payment of minimum annual spend for remaining years, less saved costs
The filing
Written by AI on Nov 9, 2026, 11:44 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 04, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.